Achieve Life Sciences is expected to report a consensus loss of $0.20 per share on $0.00 in revenue for Q3 2026, while its current price of $6.61 remains at a significant discount to the average analyst price target of $14.15.
Investors are primarily focused on the company’s progress toward resubmitting its New Drug Application (NDA) for cytisinicline, a smoking cessation aid, which is targeted for Q4 2026.
The resubmission follows a June 2026 FDA Complete Response Letter concerning third-party manufacturing issues at a previous site. Achieve has since transitioned production to a U.S.-based facility and maintains a cash runway estimated to last through the anticipated approval and potential commercial launch in early 2027.